Klinik für Innere Medizin IV, Onkologie/Hämatologie/Hämostaseologie am Universitätsklinikum Halle (Saale), Ernst-Grube-Strasse 40, Halle 06120, Germany.
The use of cisplatin-based combination chemotherapy has led to a dramatic improvement in the cure rate of patients with metastatic germ cell tumors (GCTs). With high complete response (CR) rates achieved in approximately 80% of patients with advanced testicular cancer after standard first-line cisplatin-based chemotherapy. Thereafter, the goals of various trials were to reduce the chemotherapy toxicity by limiting the number of chemotherapy cycles, the duration of therapy, and reducing the doses of, or even omitting, individual cytotoxic drugs, while maintaining efficacy, or to investigate the potential role of carboplatin as single agent or combined with etoposide and bleomycin for advanced seminoma. From prospective randomized trials and available data from additional sources, a European standard has been defined in several consensus conferences,(1-3) with the most recent consensus conference published by the European Society for Medical Oncology Consensus Group.(4,5) These international guidelines were developed from the previous published guidelines and data from available current trials. The principles of evidence-based medicine were scored (score 1-4) using a modified version of the Oxford levels of evidence and are listed in the present report in brackets. Draft guidelines were presented at an International Consensus in Urological Disease (ICUD) meeting (Shanghai, November 2009). The writing committee compiled the results of the discussion. All participants agreed to this final update.
Written by:
Schmoll HJ, Osanto S, Kawai K, Einhorn L, Fizazi K. Are you the author?
Reference: Urology. 2011 Oct;78(4 Suppl):S456-68.
doi: 10.1016/j.urology.2011.08.001
PubMed Abstract
PMID: 21986225
UroToday.com Testicular Cancer Section
